KR101613749B1 - 파킨슨병 치료용 약학 조성물 - Google Patents

파킨슨병 치료용 약학 조성물 Download PDF

Info

Publication number
KR101613749B1
KR101613749B1 KR1020117000189A KR20117000189A KR101613749B1 KR 101613749 B1 KR101613749 B1 KR 101613749B1 KR 1020117000189 A KR1020117000189 A KR 1020117000189A KR 20117000189 A KR20117000189 A KR 20117000189A KR 101613749 B1 KR101613749 B1 KR 101613749B1
Authority
KR
South Korea
Prior art keywords
rasagiline
pramipexole
combination
levodopa
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117000189A
Other languages
English (en)
Korean (ko)
Other versions
KR20110031181A (ko
Inventor
이차크 라멘스도르프
요람 셀라
Original Assignee
파마 투 비 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101613749(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마 투 비 엘티디 filed Critical 파마 투 비 엘티디
Publication of KR20110031181A publication Critical patent/KR20110031181A/ko
Application granted granted Critical
Publication of KR101613749B1 publication Critical patent/KR101613749B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117000189A 2008-06-06 2009-06-07 파킨슨병 치료용 약학 조성물 Active KR101613749B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06
US61/059,326 2008-06-06

Publications (2)

Publication Number Publication Date
KR20110031181A KR20110031181A (ko) 2011-03-24
KR101613749B1 true KR101613749B1 (ko) 2016-04-19

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117000189A Active KR101613749B1 (ko) 2008-06-06 2009-06-07 파킨슨병 치료용 약학 조성물

Country Status (22)

Country Link
US (2) US8969417B2 (https=)
EP (1) EP2303330B2 (https=)
JP (1) JP5648216B2 (https=)
KR (1) KR101613749B1 (https=)
CN (1) CN102105169B (https=)
AU (1) AU2009254730B2 (https=)
BR (1) BRPI0914902B8 (https=)
CA (1) CA2726833C (https=)
CL (1) CL2010001358A1 (https=)
CY (1) CY1119865T1 (https=)
DK (1) DK2303330T4 (https=)
ES (1) ES2659394T5 (https=)
HU (1) HUE037974T2 (https=)
LT (1) LT2303330T (https=)
MX (1) MX2010013393A (https=)
NO (1) NO2303330T3 (https=)
NZ (1) NZ590291A (https=)
PL (1) PL2303330T5 (https=)
PT (1) PT2303330T (https=)
RU (1) RU2540470C9 (https=)
WO (1) WO2009147681A1 (https=)
ZA (1) ZA201100034B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607595C2 (ru) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
WO2013105092A1 (en) * 2012-01-12 2013-07-18 Pharma Two B Ltd. Fixed dose combination therapy of parkinson's disease
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
US20150216850A1 (en) * 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
PT3302454T (pt) 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US20190343780A1 (en) * 2016-12-22 2019-11-14 Rvx Therapeutics Ltd. Low dose drug combinations for use in preventing and treating neuronal damage
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
CN113924086A (zh) * 2019-04-17 2022-01-11 维奇健康科学有限责任公司 液体药物组合物
CA3139559A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
JP2023504876A (ja) 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202227131A (zh) * 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) † 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
ATE258067T1 (de) * 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20090325911A1 (en) 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
CA2642593C (en) 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
WO2008013860A2 (en) 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
JP2010501566A (ja) 2006-08-21 2010-01-21 プレクサ ファーマシューティカルズ， インコーポレイテッド 中枢神経系障害の治療において使用するための多伝達物質トランスポータ阻害剤
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
ES2433118T3 (es) 2006-11-01 2013-12-09 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
US20100092554A1 (en) † 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
CN102105169B (zh) 2014-09-10
BRPI0914902B8 (pt) 2022-04-12
NO2303330T3 (https=) 2018-04-14
JP5648216B2 (ja) 2015-01-07
JP2011522035A (ja) 2011-07-28
AU2009254730B2 (en) 2014-06-26
EP2303330B1 (en) 2017-11-15
RU2540470C9 (ru) 2015-07-20
NZ590291A (en) 2013-11-29
PL2303330T5 (pl) 2021-10-25
BRPI0914902B1 (pt) 2022-02-22
CN102105169A (zh) 2011-06-22
DK2303330T4 (da) 2021-09-13
US8969417B2 (en) 2015-03-03
CL2010001358A1 (es) 2011-08-19
RU2540470C2 (ru) 2015-02-10
RU2010154716A (ru) 2012-08-10
PT2303330T (pt) 2018-02-12
WO2009147681A1 (en) 2009-12-10
ZA201100034B (en) 2012-04-25
US20150133513A1 (en) 2015-05-14
CY1119865T1 (el) 2018-06-27
US9259418B2 (en) 2016-02-16
AU2009254730A1 (en) 2009-12-10
LT2303330T (lt) 2018-04-10
PL2303330T3 (pl) 2018-04-30
EP2303330A1 (en) 2011-04-06
ES2659394T5 (es) 2021-12-13
CA2726833A1 (en) 2009-12-10
MX2010013393A (es) 2011-06-21
BRPI0914902A2 (pt) 2017-06-20
HUE037974T2 (hu) 2018-09-28
DK2303330T3 (en) 2018-02-26
US20110230513A1 (en) 2011-09-22
KR20110031181A (ko) 2011-03-24
CA2726833C (en) 2016-03-22
EP2303330B2 (en) 2021-06-16
ES2659394T3 (es) 2018-03-15

Similar Documents

Publication Publication Date Title
KR101613749B1 (ko) 파킨슨병 치료용 약학 조성물
Bonuccelli et al. Role of dopamine receptor agonists in the treatment of early Parkinson's disease
AU2013224960B2 (en) New therapeutic approaches for treating Parkinson's disease
Chew et al. The role of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease-an update
RU2125448C1 (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
EP3563841A1 (en) New therapeutic approaches for treating parkinson's disease
Lee et al. Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway
EP2968223B1 (en) Phenylephrine resinate particles
HK1156218B (en) Pharmaceutical compositions for treatment of parkinson's disease
HK1156218A (en) Pharmaceutical compositions for treatment of parkinson's disease
WO2020061404A1 (en) Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
EP2968224B1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US10864192B2 (en) Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
EP2968188B1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
HASSAN et al. INTERNATIONAL JOURNAL OF MEDICAL & PHARMACEUTICAL SCIENCES RESEARCH & REVIEW
Lewerenz et al. Chronic Glutamate Toxicity in
HK1203847A1 (en) Fixed dose combination therapy of parkinson's disease
HK1203847B (en) Fixed dose combination therapy of parkinson's disease
HK1219885B (en) Phenylephrine resinate particles

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140520

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151015

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160119

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160412

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160412

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190405

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190405

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200407

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200407

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210402

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210402

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20220401

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20220401

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230330

Start annual number: 8

End annual number: 8